Revvity, Inc. (NYSE:RVTY) Position Boosted by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC boosted its position in Revvity, Inc. (NYSE:RVTY) by 220.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,931 shares of the company’s stock after buying an additional 6,836 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Revvity were worth $1,108,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Assetmark Inc. increased its holdings in shares of Revvity by 3,700.0% in the 4th quarter. Assetmark Inc. now owns 266 shares of the company’s stock valued at $30,000 after acquiring an additional 259 shares during the last quarter. Millstone Evans Group LLC acquired a new position in Revvity in the fourth quarter worth $38,000. MassMutual Private Wealth & Trust FSB increased its stake in Revvity by 55.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 385 shares of the company’s stock valued at $43,000 after purchasing an additional 138 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Revvity by 33.5% during the fourth quarter. EverSource Wealth Advisors LLC now owns 522 shares of the company’s stock worth $58,000 after purchasing an additional 131 shares during the period. Finally, GeoWealth Management LLC bought a new position in shares of Revvity in the 4th quarter worth about $60,000. Institutional investors own 86.65% of the company’s stock.

Insider Activity

In other Revvity news, insider Joel S. Goldberg sold 15,170 shares of the company’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the completion of the sale, the insider now directly owns 33,400 shares of the company’s stock, valued at approximately $4,232,782. This represents a 31.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.68% of the company’s stock.

Revvity Stock Performance

Shares of NYSE RVTY opened at $95.20 on Friday. Revvity, Inc. has a 1 year low of $88.53 and a 1 year high of $129.50. The firm has a market cap of $11.44 billion, a P/E ratio of 43.08, a PEG ratio of 3.82 and a beta of 1.07. The stock has a fifty day moving average price of $105.22 and a two-hundred day moving average price of $113.28. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Friday, January 31st. The company reported $1.42 EPS for the quarter, topping the consensus estimate of $1.37 by $0.05. Revvity had a net margin of 9.81% and a return on equity of 7.68%. During the same period in the previous year, the firm earned $1.25 EPS. Research analysts forecast that Revvity, Inc. will post 4.94 EPS for the current fiscal year.

Revvity Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, August 8th. Shareholders of record on Friday, July 18th will be issued a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.29%. Revvity’s dividend payout ratio is currently 12.67%.

Analyst Ratings Changes

RVTY has been the topic of several research reports. Wells Fargo & Company dropped their price objective on shares of Revvity from $130.00 to $102.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 17th. Sanford C. Bernstein downgraded Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 price target on the stock. in a report on Friday, January 10th. Robert W. Baird reduced their price objective on Revvity from $141.00 to $127.00 and set an “outperform” rating for the company in a research report on Monday. Raymond James reaffirmed an “outperform” rating and issued a $145.00 target price (up from $140.00) on shares of Revvity in a research report on Monday, February 3rd. Finally, Barclays reduced their price target on shares of Revvity from $140.00 to $110.00 and set an “overweight” rating for the company in a report on Thursday, April 10th. Four analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $130.50.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.